Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra M Swain

Showing results (171-180 of 210) with videos related to

Pageof 21
Sort By:
Breast Cancer Research and Treatment|May 4, 2022
Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)Charles E Geyer, Hanna Bandos, Priya Rastogi, et al.
Breast Cancer Research and Treatment|March 1, 2022
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)Charles E Geyer, Hanna Bandos, Priya Rastogi, et al.
NPJ Breast Cancer|September 30, 2024
Pharmacokinetics and pharmacogenomics of ribociclib in black patients with metastatic breast cancer the LEANORA studyIlana Schlam, D Max Smith, Cody Peer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2006
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancerSuparna Bonthala Wedam, Jennifer A Low, Sherry X Yang, et al.
Breast Cancer Research and Treatment|March 22, 2023
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41Priya Rastogi, Gong Tang, Saima Hassan, et al.
The Oncologist|December 2, 2025
Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studiesYeon Hee Park, Javier Cortes, Shanu Modi, et al.
Breast Cancer Research and Treatment|April 23, 2019
Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North AfricaCatherine Schairer, Ahmed Hablas, Ibrahim AbdelBar Seif Eldein, et al.
Frontiers in Oncology|June 12, 2023
Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trialPooja P Advani, Kathryn J Ruddy, Joerg Herrmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2019
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2Louis Fehrenbacher, Reena S Cecchini, Charles E Geyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2024
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 TrialPriya Rastogi, Hanna Bandos, Peter C Lucas, et al.
Pageof 21

Showing results (171-180 of 210) with videos related to

Sort By:
Pageof 21
Breast Cancer Research and Treatment|May 4, 2022
Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)Charles E Geyer, Hanna Bandos, Priya Rastogi, et al.
Breast Cancer Research and Treatment|March 1, 2022
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)Charles E Geyer, Hanna Bandos, Priya Rastogi, et al.
NPJ Breast Cancer|September 30, 2024
Pharmacokinetics and pharmacogenomics of ribociclib in black patients with metastatic breast cancer the LEANORA studyIlana Schlam, D Max Smith, Cody Peer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2006
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancerSuparna Bonthala Wedam, Jennifer A Low, Sherry X Yang, et al.
Breast Cancer Research and Treatment|March 22, 2023
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41Priya Rastogi, Gong Tang, Saima Hassan, et al.
The Oncologist|December 2, 2025
Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studiesYeon Hee Park, Javier Cortes, Shanu Modi, et al.
Breast Cancer Research and Treatment|April 23, 2019
Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North AfricaCatherine Schairer, Ahmed Hablas, Ibrahim AbdelBar Seif Eldein, et al.
Frontiers in Oncology|June 12, 2023
Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trialPooja P Advani, Kathryn J Ruddy, Joerg Herrmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2019
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2Louis Fehrenbacher, Reena S Cecchini, Charles E Geyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2024
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 TrialPriya Rastogi, Hanna Bandos, Peter C Lucas, et al.
Pageof 21